Daily Respiratory Research Analysis
Three high-impact respiratory studies stood out: an AI-discovered, first-in-class TNIK inhibitor (rentosertib) showed acceptable safety in a randomized phase 2a trial for idiopathic pulmonary fibrosis; a mechanistic study unveiled a host-directed antiviral strategy by preventing virus-induced TFEB degradation via DCAF7 inhibition, achieving efficacy in two SARS-CoV-2 animal models; and a phase 3 immunobridging trial demonstrated that the mRNA-1345 RSV vaccine elicited neutralizing antibodies in
Summary
Three high-impact respiratory studies stood out: an AI-discovered, first-in-class TNIK inhibitor (rentosertib) showed acceptable safety in a randomized phase 2a trial for idiopathic pulmonary fibrosis; a mechanistic study unveiled a host-directed antiviral strategy by preventing virus-induced TFEB degradation via DCAF7 inhibition, achieving efficacy in two SARS-CoV-2 animal models; and a phase 3 immunobridging trial demonstrated that the mRNA-1345 RSV vaccine elicited neutralizing antibodies in at-risk adults aged 18–59 years noninferior to those in older adults.
Research Themes
- AI-designed therapeutics in fibrotic lung disease
- Host-directed antiviral mechanisms via lysosomal/TFEB pathways
- Immunobridging evidence for RSV vaccination in at-risk younger adults
Selected Articles
1. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.
This multicenter, double-blind, randomized phase 2a trial tested the AI-generated TNIK inhibitor rentosertib in IPF and found similar treatment-emergent adverse event rates across three dose arms versus placebo over 12 weeks. Safety signals were manageable, supporting further development of a first-in-class, AI-designed antifibrotic.
Impact: This is among the first randomized trials of an AI-designed, first-in-class small molecule in a fatal fibrotic lung disease, demonstrating translational feasibility and acceptable safety.
Clinical Implications: While early-phase and safety-focused, these data support advancing rentosertib into larger efficacy trials in IPF, potentially expanding the therapeutic landscape beyond current antifibrotics.
Key Findings
- Randomized, double-blind, placebo-controlled phase 2a trial in IPF (12 weeks, 4 arms: 30 mg QD, 30 mg BID, 60 mg QD, placebo).
- Treatment-emergent adverse events occurred at similar rates across rentosertib and placebo arms (approximately 70–83%).
- Serious adverse events were infrequent; discontinuations were mainly due to liver toxicity or diarrhea.
- First-in-class TNIK inhibition and AI-generated design represent a novel therapeutic strategy for IPF.
Methodological Strengths
- Multicenter, double-blind, randomized, placebo-controlled design
- Clear pre-specified safety primary endpoint with dose-ranging arms
Limitations
- Small total sample size (~71) and short duration (12 weeks)
- Primary endpoint focused on safety; efficacy outcomes are exploratory
Future Directions: Proceed to larger, longer, efficacy-focused phase 2b/3 trials to assess lung function decline (e.g., FVC), progression-free survival, imaging and biomarker responses, and to refine dose.
Despite substantial progress in artificial intelligence (AI) for generative chemistry, few novel AI-discovered or AI-designed drugs have reached human clinical trials. Here we present the results of the first phase 2a multicenter, double-blind, randomized, placebo-controlled trial testing the safety and efficacy of rentosertib (formerly ISM001-055), a first-in-class AI-generated small-molecule inhibitor of TNIK, a first-in-class target in idiopathic pulmonary fibrosis (IPF) discovered using generative AI. IPF is an age-related progressive lung condition with no current therapies available that reverse the degenerative course of disease. Patients were randomized to 12 weeks of treatment with 30 mg rentosertib once daily (QD, n = 18), 30 mg rentosertib twice daily (BID, n = 18), 60 mg rentosertib QD (n = 18) or placebo (n = 17). The primary endpoint was the percentage of patients who have at least one treatment-emergent adverse event, which was similar across all treatment arms (72.2% in patients receiving 30 mg rentosertib QD (n = 13/18), 83.3% for 30 mg rentosertib BID (n = 15/18), 83.3% for 60 mg rentosertib QD (n = 15/18) and 70.6% for placebo (n = 12/17)). Treatment-related serious adverse event rates were low and comparable across treatment groups, with the most common events leading to treatment discontinuation related to liver toxicity or diarrhea. Secondary endpoints included pharmacokinetic dynamics (C
2. Inhibition of virally induced TFEB proteasomal degradation as a host-centric therapeutic approach for coronaviral infection.
The study identifies DCAF7- and PAK2-mediated proteasomal degradation of TFEB as a viral strategy to impair lysosomal homeostasis. Novel small molecules blocking DCAF7–TFEB interaction restored TFEB and exhibited broad antiviral activity, attenuating SARS-CoV-2 infection in two animal models.
Impact: Reveals a previously unknown host-pathway hijack by coronaviruses and delivers drug-like inhibitors with in vivo efficacy, defining a new host-directed antiviral class.
Clinical Implications: While preclinical, these findings support development of DCAF7 inhibitors as broad-spectrum antivirals less susceptible to viral escape, complementing direct-acting agents.
Key Findings
- Coronaviruses trigger proteasomal degradation of TFEB, the master regulator of lysosomal homeostasis.
- TFEB stability is co-regulated by DCAF7 (E3 ligase subunit) and PAK2 kinase identified via proteomics and siRNA screening.
- Small molecules disrupting DCAF7–TFEB interaction prevent TFEB degradation and exhibit broad antiviral activity.
- Efficacy demonstrated by attenuation of SARS-CoV-2 infection in two animal models.
Methodological Strengths
- Multi-modal mechanistic approach (mass spectrometry, unbiased RNAi screen, chemical biology)
- In vivo validation in two independent SARS-CoV-2 animal models
Limitations
- Preclinical study; human safety and efficacy are unknown
- Scope limited to coronaviral models; breadth across other respiratory viruses requires testing
Future Directions: Advance lead DCAF7 inhibitors into IND-enabling studies, define PK/PD–biomarker relationships (e.g., TFEB target engagement), and evaluate spectrum against diverse respiratory viruses.
The endolysosomal pathway plays an evolutionarily conserved role in pathogen clearance, and viruses have evolved complex mechanisms to evade this host defense system. Here, we describe a previously unidentified aspect of coronaviral infection, whereby the master transcriptional activator of lysosomal homeostasis-TFEB-is targeted for proteasomal-mediated degradation upon viral infection. Through mass spectrometry analysis and an unbiased small interfering RNA screen, we identify that TFEB protein stability is coordinately regulated by the E3 ubiquitin ligase subunit DCAF7 and the PAK2 kinase. We derive a series of novel small molecules that interfere with the DCAF7-TFEB interaction. These agents inhibit virus-induced TFEB degradation and demonstrate broad antiviral activities including attenuating severe acute respiratory syndrome coronavirus 2 infection in two animal models. Together, these results delineate a virally triggered pathway that impairs lysosomal homeostasis in the host. Small molecule E3 ubiquitin ligase DCAF7 inhibitors that restore lysosomal function represent a novel class of host-directed, antiviral therapies useful for current and potentially future coronaviral variants.
3. Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years.
In at-risk adults aged 18–59 years, a single 50 µg dose of mRNA-1345 was well tolerated and achieved Day 29 neutralizing antibody GMTs against RSV-A and RSV-B that were noninferior to those in ≥60-year-olds from the pivotal trial, with responses persisting through Day 181.
Impact: Provides immunobridging evidence supporting efficacy inference and potential label expansion of an RSV mRNA vaccine to younger at-risk adults.
Clinical Implications: If authorized, immunization of at-risk adults 18–59 could reduce RSV-LRTD burden; data support 50 µg dosing with acceptable tolerability and durable neutralization.
Key Findings
- Randomized, double-blind phase 3 immunogenicity and safety study in at-risk adults aged 18–59 (n=999).
- Day 29 nAb GMTs for 50 µg met noninferiority versus ≥60-year-olds from the pivotal efficacy trial (RSV-A GMR 1.2; RSV-B GMR 1.1).
- Seroresponse noninferiority also achieved; immune responses persisted above baseline to Day 181.
- Solicited adverse reactions were mostly mild–moderate and transient (median 2 days).
Methodological Strengths
- Randomized, double-blind design with dose comparison
- Prespecified immunobridging to pivotal efficacy cohort enabling inference of efficacy
Limitations
- Immunobridging to historical cohort rather than direct clinical efficacy in this age group
- Follow-up limited to Day 181 for persistence; long-term effectiveness and safety beyond this remain to be shown
Future Directions: Conduct effectiveness studies in diverse at-risk subgroups, evaluate clinical endpoints (RSV-LRTD reduction), durability beyond 6 months, and coadministration strategies.
BACKGROUND: Respiratory syncytial virus (RSV) is a significant health risk for adults aged 18-59 years with chronic medical conditions. METHODS: This ongoing, randomized, double-blind Phase 3 trial evaluates safety and immunogenicity of the RSV vaccine, mRNA-1345, in adults aged 18-59 years at increased risk for RSV-associated lower respiratory tract disease (LRTD). Participants received a single 50-µg (licensed dose) or 30-µg dose. Co-primary immunogenicity objectives were to demonstrate noninferiority of Day 29 RSV-A and RSV-B neutralizing antibody (nAb) geometric mean titers (GMTs) for the 50-μg dose compared to those observed in adults aged ≥60 years from the Phase 3 pivotal efficacy trial. The other primary objective was to evaluate safety and tolerability. RESULTS: 999 participants received mRNA-1345 (50-µg, n=502; 30-µg, n=497). Most solicited adverse reactions (ARs) were mild to moderate with a median duration of 2 days. Injection-site pain, fatigue, headache, and myalgia were the most common ARs. Day 29 nAb GMTs in the 50-µg group met noninferiority criteria: RSV-A GMT ratio (GMR) was 1.2 (95% CI: 1.1-1.3); RSV-B GMR was 1.1 (95% CI: 1.0-1.2). Noninferiority was also demonstrated for seroresponse rate differences: RSV-A at 11.8% (95% CI: 7.8-15.5); RSV-B at 10.8% (95% CI: 5.9-15.6). Immune responses were consistent across subgroups and remained above baseline through Day 181. CONCLUSIONS: In adults aged 18-59 years at increased risk for RSV-LRTD, a 50-µg dose of mRNA-1345 was well-tolerated and elicited RSV-A and RSV-B nAb responses noninferior to those observed in older adults in the pivotal study, supporting inference of efficacy in this population. CLINICAL TRIAL REGISTRATION NUMBER: NCT06067230.